Role of the tissue factor pathway in the biology of tumor initiating cells

Thrombosis Research

Volumn 125, Issue , 2010, Pages S44-S50

  Garnier, Delphine ^a   Milsom, Chloe ^b   Magnus, Nathalie ^a   Meehan, Brian ^a   Weitz, Jeffrey ^c   Yu, Joanne ^b   Rak, Janusz ^a  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Cancer; Cancer stem cell niche; Cancer stem cells; Coagulation; Oncogenes; Tissue factor

Indexed keywords

PROTEINASE ACTIVATED RECEPTOR; THROMBOPLASTIN;

ANIMAL; ARTICLE; CANCER STEM CELL; CELL DIFFERENTIATION; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOPLASM; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PATHOLOGY;

ANIMALS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NEOPLASTIC PROCESSES; NEOPLASTIC STEM CELLS; RECEPTORS, PROTEINASE-ACTIVATED; THROMBOPLASTIN;

EID: 77955502182     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(10)70012-8     Document Type: Article

References (104)

1. Vogelstein, B, Kinzler, KW, Cancer genes and the pathways they control. Nat Med 10 (2004), 789–799.
2. Hanahan, D, Weinberg, RA, The hallmarks of cancer. Cell 100 (2000), 57–70.
3. Rak, J, Milsom, C, Yu, J, Tissue factor in cancer. Curr Opin Hematol 15 (2008), 522–528.
4. Folkman, J, Kalluri, R, Tumor Angiogenesis. Kufe, DW, Pollock, RE, Weichselbaum, RR, et al. (eds.) Cancer Medicine, 2003, BC Decker Inc, Hamilton, London, 161–194.
5. Al-Nedawi, K, Meehan, B, Rak, J, Microvesicles: messengers and mediators of tumor progression. Cell Cycle 8 (2009), 2014–2018.
6. Rak, J, Kerbel, RS, Oncogenes and tumor angiogenesis. Rak, J, (eds.) Oncogene-Directed Therapies, 2003, Humana Press, Totowa, 171–218.
7. Heppner, GH, Tumor heterogeneity. Cancer Res 44 (1989), 2259–2265.
8. Heppner, GH, Tumor cell societies. J Natl Canc Inst 81 (1989), 648–649.
9. Dick, JE, Stem cell concepts renew cancer research. Blood 112 (2008), 4793–4807.
10. Reya, T, Morrison, SJ, Clarke, MF, Weissman, IL, Stem cells, cancer, and cancer stem cells. Nature 414 (2001), 105–111.
11. Zhu, L, Gibson, P, Currle, DS, et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 457 (2009), 603–607.
12. Dirks, PB, Brain tumor stem cells: bringing order to the chaos of brain cancer. J Clin Oncol 26 (2008), 2916–2924.
13. Thiery, JP, Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15 (2003), 740–746.
14. Mani, SA, Guo, W, Liao, MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008), 704–715.
15. Milsom, CC, Yu, JL, Mackman, N, et al. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res 68 (2008), 10068–10076.
16. Al-Hajj, M, Wicha, MS, Benito-Hernandez, A, Morrison, SJ, Clarke, MF, Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100 (2003), 3983–3988.
17. Dick, JE, Looking ahead in cancer stem cell research. Nat Biotechnol 27 (2009), 44–46.
18. Stiles, CD, Rowitch, DH, Glioma stem cells: a midterm exam. Neuron 58 (2008), 832–846.
19. Hill, RP, Perris, R, “Destemming” cancer stem cells. J Natl Cancer Inst 99 (2007), 1435–1440.
20. Rak, J, Is cancer stem cell a cell, or a multicellular unit capable of inducing angiogenesis?. Med Hypotheses 66 (2006), 601–604.
21. Quintana, E, Shackleton, M, Sabel, MS, et al. Efficient tumour formation by single human melanoma cells. Nature 456 (2008), 593–598.
22. Baker, CH, Solorzano, CC, Fidler, IJ, Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 62 (2002), 1996–2003.
23. Li, F, Tiede, B, Massague, J, Kang, Y, Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 17 (2007), 3–14.
24. Shen, Q, Wang, Y, Kokovay, E, et al. Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of niche cell-cell interactions. Cell Stem Cell 3 (2008), 289–300.
25. Gilbertson, RJ, Rich, JN, Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 7 (2007), 733–736.
26. Calabrese, C, Poppleton, H, Kocak, M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11 (2007), 69–82.
27. Bao, S, Wu, Q, Sathornsumetee, S, et al. Stem Cell-like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor. Cancer Res 66 (2006), 7843–7848.
28. Li, Z, Bao, S, Wu, Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15 (2009), 501–513.
29. Folkins, C, Man, S, Xu, P, et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67 (2007), 3560–3564.
30. Kaplan, RN, Riba, RD, Zacharoulis, S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 (2005), 820–827.
31. Rak, J, Filmus, J, Kerbel, RS, Reciprocal paracrine interactions between tumour cells and endothelial cells: the ‘angiogenesis progression’ hypothesis. Eur J Cancer 32A (1996), 2438–2450.
32. Nicosia, RF, Tchao, R, Leighton, J, Angiogenesis-dependent tumor spread in reinforced fibrin clot culture. Cancer Res 43 (1983), 2159–2166.
33. Milsom, C, Magnus, N, Meehan, B, et al. Tissue factor and cancer stem cells. Is there a linkage?. Arterioscler Thromb Vasc Biol, 2009 in press.
34. Mueller, BM, Reisfeld, RA, Edgington, TS, Ruf, W, Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 89 (1992), 11832–11836.
35. Bromberg, ME, Sundaram, R, Homer, RJ, Garen, A, Konigsberg, WH, Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 82 (1999), 88–92.
36. Palumbo, JS, Talmage, KE, Massari, JV, et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 110 (2007), 133–141.
37. Francis, JL, Amirkhosravi, A, Effect of antihemostatic agents on experimental tumor dissemination. Semin Thromb Hemost 28 (2002), 29–38.
38. Rickles, FR, Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 35 (2006), 103–110.
39. Dvorak, FH, Rickles, FR, Malignancy and Hemostasis. Coleman, RB, Marder, VJ, Clowes, AW, George, JN, Goldhaber, SZ, (eds.) Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 2006, Lippincott Company Williams & Wilkins, Philadelphia, 851–873.
40. Buller, HR, van Doormaal, FF, van Sluis, GL, Kamphuisen, PW, Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 5:Suppl 1 (2007), 246–254.
41. Falanga, A, Thrombophilia in cancer. Semin Thromb Hemost 31 (2005), 104–110.
42. Petralia, GA, Lemoine, NR, Kakkar, AK, Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol 2 (2005), 356–363.
43. Lee, AY, Rickles, FR, Julian, JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23 (2005), 2123–2129.
44. Trousseau, A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris. Paris: France; 1865. The Sydenham Society 2nd, 654–712.
45. Varki, A, Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 110 (2007), 1723–1729.
46. Zwicker, JI, Furie, BC, Furie, B, Cancer-associated thrombosis. Crit Rev Oncol Hematol 62 (2007), 126–136.
47. Boccaccio, C, Sabatino, G, Medico, E, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 434 (2005), 396–400.
48. Rong, Y, Belozerov, VE, Tucker-Burden, C, et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res 69 (2009), 2540–2549.
49. Yu, JL, May, L, Lhotak, V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 105 (2005), 1734–1741.
50. Mackman, N, Triggers, targets and treatments for thrombosis. Nature 451 (2008), 914–918.
51. Contrino, J, Hair, G, Kreutzer, DL, Rickles, FR, In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 2 (1996), 209–215.
52. Dvorak, HF, Quay, SC, Orenstein, NS, et al. Tumor shedding and coagulation. Science 212 (1981), 923–924.
53. Furie, B, Furie, BC, Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 10 (2004), 171–178.
54. Tesselaar, ME, Romijn, FP, van der Linden, IK, et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost 5 (2007), 520–527.
55. Aharon, A, Brenner, B, Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol 22 (2009), 61–69.
56. Brat, DJ, Van Meir, EG, Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 84 (2004), 397–405.
57. Ahmed, TA, Dare, EV, Hincke, M, Fibrin: A versatile scaffold for tissue engineering applications. Tissue Eng Part B Rev, 2008.
58. Moldovan, NI, Asahara, T, Role of blood mononuclear cells in recanalization and vascularization of thrombi: past, present, and future. Trends Cardiovasced 13 (2003), 265–269.
59. Ruf, W, Redundant signaling of tissue factor and thrombin in cancer progression?. J Thromb Haemost 5 (2007), 1584–1587.
60. Versteeg, HH, Schaffner, F, Kerver, M, et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 111 (2008), 190–199.
61. Bhattacharjee, G, Ahamed, J, Pedersen, B, et al. Regulation of tissue factor – mediated initiation of the coagulation cascade by cell surface grp78. Arterioscler. Thromb Vasc Biol 25 (2005), 1737–1743.
62. Rak, J, Klement, G, Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. Cancer Metastasis Rev 19 (2000), 93–96.
63. Yu, JL, May, L, Klement, P, Weitz, JI, Rak, J, Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy. Semin Thromb Hemost 30 (2004), 21–30.
64. Magnus, N. The Role of Tissue Factor in the Progression and Angiogenesis of Malignant Glioma. MSc Thesis, McGill University; 2009, p. 1–92.
65. Yu, JL, Rak, JW, Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2 (2004), 2065–2067.
66. Yu, J, May, L, Milsom, C, et al. Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol 28 (2008), 1975–1981.
67. Al-Nedawi, K, Meehan, B, Micallef, J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10 (2008), 619–624.
68. Provencal, M, Labbe, D, Veitch, R, et al. C-Met activation in medulloblastoma induces tissue factor expression and activity: effects on cell migration. Carcinogenesis, 2009.
69. Tallman, MS, Lefebvre, P, Baine, RM, et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2 (2004), 1341–1350.
70. Rak, J, Yu, JL, Luyendyk, J, Mackman, N, Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 66 (2006), 10643–10646.
71. Rong, Y, Post, DE, Pieper, RO, et al. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 65 (2005), 1406–1413.
72. Milsom, C, Rak, J, Regulation of tissue factor and angiogenesis-related genes by changes in cell shape. Biochem Biophys Res Commun 337 (2005), 1267–1275.
73. Carmeliet, P, Mackman, N, Moons, L, et al. Role of tissue factor in embryonic blood vessel development. Nature 383 (1996), 73–75.
74. Coughlin, SR, Thrombin signalling and protease-activated receptors. Nature 407 (2000), 258–264.
75. Mackman, N, Tissue-specific hemostasis: role of tissue factor. J Thromb Haemost 6 (2008), 303–305.
76. Liu, TM, Wu, YN, Guo, XM, et al. Effects of ectopic Nanog and Oct4 overexpression on mesenchymal stem cells. Stem Cells Dev 18 (2008), 1013–1022.
77. Parisi, S, Passaro, F, Aloia, L, et al. Klf5 is involved in self-renewal of mouse embryonic stem cells. J Cell Sci 121 (2008), 2629–2634.
78. Ema, M, Mori, D, Niwa, H, et al. Kruppel-like factor 5 is essential for blastocyst development and the normal self-renewal of mouse ESCs. Cell Stem Cell 3 (2008), 555–567.
79. Jiang, J, Chan, YS, Loh, YH, et al. A core Klf circuitry regulates self-renewal of embryonic stem cells. Nat Cell Biol 10 (2008), 353–360.
80. Davey, RE, Onishi, K, Mahdavi, A, Zandstra, PW, LIF-mediated control of embryonic stem cell self-renewal emerges due to an autoregulatory loop. FASEB J 21 (2007), 2020–2032.
81. Bauer, S, Patterson, PH, Leukemia inhibitory factor promotes neural stem cell self-renewal in the adult brain. J Neurosci 26 (2006), 12089–12099.
82. Camerer, E, Gjernes, E, Wiiger, M, Pringle, S, Prydz, H, Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem 275 (2000), 6580–6585.
83. Milsom, C, Anderson, GM, Weitz, JI, Rak, J, Elevated tissue factor procoagulant activity in CD133-positive cancer cells. J Thromb Haemost 5 (2007), 2550–2552.
84. Albrektsen, T, Sorensen, BB, Hjorto, GM, et al. Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells. J Thromb Haemost 5 (2007), 1588–1597.
85. Theodorou, E, Dalembert, G, Heffelfinger, C, et al. A high throughput embryonic stem cell screen identifies Oct-2 as a bifunctional regulator of neuronal differentiation. Genes Dev 23 (2009), 575–588.
86. Petersen, LC, Microarray studies of factor VIIa-activated cancer cells. Thromb Res 122:Suppl 1 (2008), S11–S13.
87. Si, W, Kang, Q, Luu, HH, et al. CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol Cell Biol 26 (2006), 2955–2964.
88. Luo, Q, Kang, Q, Si, W, et al. Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J Biol Chem 279 (2004), 55958–55968.
89. Pendurthi, UR, Allen, KE, Ezban, M, Rao, LV, Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa × tissue factor-induced signal transduction. J Biol Chem 275 (2000), 14632–14641.
90. Wang, X, Wang, M, Amarzguioui, M, et al. Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice. Int J Cancer 112 (2004), 994–1002.
91. Martin, K, Weiss, S, Metharom, P, et al. Thrombin stimulates smooth muscle cell differentiation from peripheral blood mononuclear cells via protease-activated receptor-1, RhoA, and myocardin. Circ Res 105 (2009), 214–218.
92. Tarzami, ST, Wang, G, Li, W, Green, L, Singh, JP, Thrombin and PAR-1 stimulate differentiation of bone marrow-derived endothelial progenitor cells. J Thromb Haemost 4 (2006), 656–663.
93. Grassinger, J, Haylock, DN, Storan, MJ, et al. Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. Blood 114 (2009), 49–59.
94. Bertout, JA, Patel, SA, Simon, MC, The impact of O2 availability on human cancer. Nat Rev Cancer 8 (2008), 967–975.
95. Rong, Y, Durden, DL, Van Meir, EG, Brat, DJ, “Pseudopalisading” necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 65 (2006), 529–539.
96. Toomey, JR, Kratzer, KE, Lasky, NM, Broze, GJ Jr, Effect of tissue factor deficiency on mouse and tumor development. Proc Natl Acad Sci USA 94 (1997), 6922–6926.
97. Parry, GC, Erlich, JH, Carmeliet, P, Luther, T, Mackman, N, Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest 101 (1998), 560–569.
98. Ngo, CV, Manning, CA, McCabe, F, et al. Combination antibody therapy targeting both xenograft- and host-derived tissue factor leads to potent tumor inhibition [abstract]. Proc Am Assoc Cancer Res, 46, 2005 Abstract #548.
99. Viloria-Petit, A, Miquerol, L, Yu, JL, et al. Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J 22 (2003), 4091–4102.
100. Milsom, C.C. Regulation of Tissue Factor in Cancer. PhD Thesis, McMaster University; 2009, p. 1–270.
101. Gessler, F, Voss, V, Dutzmann, S, et al. Inhibition of tissue factor/protease-activated receptor-2 signaling limits proliferation, migration and invasion of malignant glioma cells. Neuroscience, 2009.
102. Ngo, CV, Picha, K, McCabe, F, et al. CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models. Int J Cancer 120 (2007), 1261–1267.
103. Hembrough, TA, Swartz, GM, Papathanassiu, A, et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 63 (2003), 2997–3000.
104. Zhao, J, Aguilar, G, Palencia, S, Newton, E, Abo, A, rNAPc2 inhibits colorectal cancer in mice through tissue factor. Clin Cancer Res 15 (2009), 208–216.